Aktis Oncology (NASDAQ:AKTS) Stock Jumps 5.7% – Here’s What Happened

Aktis Oncology (NASDAQ:AKTS) shares were up 5.7% during trading on Tuesday. The company traded as high as $17.31 and last traded at $17.31. 164,301 shares traded hands during mid-day trading, a decline of 54% from the average session volume of 354,639 shares. The stock had previously closed at $16.37.

Analyst Ratings Changes

Several analysts have recently weighed in on AKTS shares. Wedbush restated an “outperform” rating and issued a $35.00 price objective on shares of Aktis Oncology in a report on Friday, October 2nd. Weiss Ratings lowered Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, October 2nd. BMO Capital Markets began coverage on shares of Aktis Oncology in a research report on Tuesday, August 18th. They issued an “outperform” rating and a $37.00 price target on the stock. JPMorgan Chase & Co. upped their price target on shares of Aktis Oncology from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Tuesday, July 14th. Finally, Wall Street Zen lowered shares of Aktis Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, July 25th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $35.62.

Aktis Oncology Trading Up 5.7%

The company has a market cap of $930.41 million and a price-to-earnings ratio of -21.13. The business has a 50-day moving average price of $19.30 and a 200 day moving average price of $20.88.

Aktis Oncology (NASDAQ:AKTS) last posted its quarterly earnings data on Thursday, August 13th. The technology company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.01). The business had revenue of $3.38 million during the quarter, compared to analysts’ expectations of $2.70 million. On average, analysts anticipate that Aktis Oncology will post -1.84 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Global Retirement Partners LLC grew its stake in Aktis Oncology by 289.1% during the 3rd quarter. Global Retirement Partners LLC now owns 1,537 shares of the technology company’s stock valued at $30,000 after acquiring an additional 1,142 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of Aktis Oncology by 8.2% in the third quarter. Russell Investments Group Ltd. now owns 8,391 shares of the technology company’s stock worth $163,000 after purchasing an additional 637 shares in the last quarter. Silver Grove Financial Group Inc. purchased a new stake in shares of Aktis Oncology in the third quarter worth approximately $28,000. Mirador Capital Partners LP boosted its holdings in shares of Aktis Oncology by 232.9% during the third quarter. Mirador Capital Partners LP now owns 133,558 shares of the technology company’s stock worth $2,600,000 after purchasing an additional 93,434 shares during the period. Finally, GK Wealth Management LLC acquired a new stake in shares of Aktis Oncology during the third quarter worth approximately $26,000. Hedge funds and other institutional investors own 28.84% of the company’s stock.

About Aktis Oncology

Aktis Oncology, Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for solid tumors. Its approach uses small protein-based molecules designed to bind cancer-associated targets and deliver radioactive payloads to tumor cells. The company’s pipeline includes investigational programs directed at targets found on solid tumors, including Nectin-4. These candidates are being developed for potential use in patients with advanced cancers; they are not approved for commercial use.